OBJECTIVE： To observe therapeutic efficacy and ADR of Gandi capsule for diabetic nephropathy. METHODS： 41 patients with diabetic nephropathy were randomly divided into control group （20 cases） and trial group （21 cases）. Both group received routine diabetes therapy scheme and diabetic diet. Based on this， control group was additionally given placebo， 3 pills/time， tid； trial group was additionally given Gandi capsules， 3 pills/time， tid. A treatment course lasted for 2 months， and all of them received 3 courses of treatment. Plasma glucose，24 h urine micro albumin quantity， liver/renal function， lipids and routine blood test were compared between 2 groups before and after treatment. RESULTS： After 4 months of treatment

clinical efficacy of trial group was better than that of control group

with statistical significance （P＜0.05）； after 6 months of treatment

total protein and albumin in blood increased in 2 groups

there was statistical significance

compared with before treatment（P＜0.05）； but there was no statistical significance between 2 groups （P＞0.05）；blood lipid of 2 groups decreased after treatment

there was no statistical significance

compared with before treatment and between 2 groups （P＞0.05）； fasting blood glucose of trial group increased slightly after treatment

but postprandial 2 h blood glucose HbA1c （reflecting 2-3 weeks average blood glucose）decreased

there was no statistical significance

compared with before treatment and control group （P＞0.05）. there was no statistical significance between 2 groups（P＞0.05）. CONCLUSIONS： Adjunctive treatment of Gandi capsule is effective for diabetic nephropathy without obvious ADR.